• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Nominees for best AbbVie blunder in the last 10 years are…

Quote




Of course its SZ. I don't know what SK and MS were thinking in promoting her to this role. Her impact to the portfolio is far reaching across all TAs/stages and with her incompetence as a leader both people and narrow technical experience, makes her damage that much worse. Also her passive aggressiveness and lying, make her such a liability as a management figure.

Its a no brainer when you look at the data.
-Looking at the projects and ask how many delays and failures can be attributed to her area.
-Ask members of her department, particularly those that are underrepresented or her direct reports, how they feel about her. Ask them to share spreadsheets that team members have compiled and distributed among themselves to her bias over the years that is tolerated by management and HR.
-Ask people who transferred out of her department, why and look at their demographics.
-Ask the OED team that transferred to her department. How long did it take for her to backtrack on initial promises and how was it that she was not outright lying at the beginning of the transfer.
-Ask the Allergan team in her area how fairly she resourced them, took interest in what they actually did and her lies along the way. Its widely known they were by far the most unlucky after the integration, see the turnover of talent and the risk it introduced to the projects that now she asks us to clean up.
 




anonymous said:
Of course its SZ. I don't know what SK and MS were thinking in promoting her to this role. Her impact to the portfolio is far reaching across all TAs/stages and with her incompetence as a leader both people and narrow technical experience, makes her damage that much worse. Also her passive aggressiveness and lying, make her such a liability as a management figure.

Its a no brainer when you look at the data.
-Looking at the projects and ask how many delays and failures can be attributed to her area.
-Ask members of her department, particularly those that are underrepresented or her direct reports, how they feel about her. Ask them to share spreadsheets that team members have compiled and distributed among themselves to her bias over the years that is tolerated by management and HR.
-Ask people who transferred out of her department, why and look at their demographics.
-Ask the OED team that transferred to her department. How long did it take for her to backtrack on initial promises and how was it that she was not outright lying at the beginning of the transfer.
-Ask the Allergan team in her area how fairly she resourced them, took interest in what they actually did and her lies along the way. It’s widely known they were by far the most unlucky after the integration, see the turnover of talent and the risk it introduced to the projects that now she asks us to clean up.
Click to expand...
Ok she wins …
 
















anonymous said:
Exiting Mike Severino. Huge loss. After he left, the bleed of talent has been terrible.
Click to expand...

Severino was tabbed to be the next CEO, but at some point post merger was told he actually wouldn’t get the job. Dude is a genius.

He left pretty abruptly thereafter. With a couple exceptions, they lost literally all AbbVie R&D leadership through the VP level. Many who left made lateral moves or straight downgrades.
 




anonymous said:
Severino was tabbed to be the next CEO, but at some point post merger was told he actually wouldn’t get the job. Dude is a genius.

He left pretty abruptly thereafter. With a couple exceptions, they lost literally all AbbVie R&D leadership through the VP level. Many who left made lateral moves or straight downgrades.
Click to expand...
What’s the sentiment on Neil Gallagher leaving?
 




anonymous said:
Severino was tabbed to be the next CEO, but at some point post merger was told he actually wouldn’t get the job. Dude is a genius.

He left pretty abruptly thereafter. With a couple exceptions, they lost literally all AbbVie R&D leadership through the VP level. Many who left made lateral moves or straight downgrades.
Click to expand...

who downgraded? I suspect they all have more decision making rights and influence and probably more money. If you mean going to a smaller company, then true but maybe they actively wanted to seek that out after their experience at AbbVie.
 




anonymous said:
What’s the sentiment on Neil Gallagher leaving?
Click to expand...
He knew what he was doing. He was an actual drug developer. He could never fit in with this lot. The RDLT is a joke with the exception of a rare few like Roopal but the rest total joke. I think Tom sees himself as a scientist more than a drug developer.

People like to say he was difficult. He wasn’t. He was frustrated by the stupidity that surrounded him and it showed.

Case in point who got added to RDLT from Allergan? The preclinical device guy who is paraded like a drug developer and the guy that worked on one approved drug his entire career but never actually developed a new drug. Both are very hated by most people in legacy Allergan. It tells you all you need to know about the judgement being exercised when people like this are the chosen few.

Now how would a seasoned drug developer like Neil fit in here with these clowns as his peers?
 




anonymous said:
He knew what he was doing. He was an actual drug developer. He could never fit in with this lot. The RDLT is a joke with the exception of a rare few like Roopal but the rest total joke. I think Tom sees himself as a scientist more than a drug developer.

People like to say he was difficult. He wasn’t. He was frustrated by the stupidity that surrounded him and it showed.

Case in point who got added to RDLT from Allergan? The preclinical device guy who is paraded like a drug developer and the guy that worked on one approved drug his entire career but never actually developed a new drug. Both are very hated by most people in legacy Allergan. It tells you all you need to know about the judgement being exercised when people like this are the chosen few.

Now how would a seasoned drug developer like Neil fit in here with these clowns as his peers?
Click to expand...
 




anonymous said:
He knew what he was doing. He was an actual drug developer. He could never fit in with this lot. The RDLT is a joke with the exception of a rare few like Roopal but the rest total joke. I think Tom sees himself as a scientist more than a drug developer.

People like to say he was difficult. He wasn’t. He was frustrated by the stupidity that surrounded him and it showed.

Case in point who got added to RDLT from Allergan? The preclinical device guy who is paraded like a drug developer and the guy that worked on one approved drug his entire career but never actually developed a new drug. Both are very hated by most people in legacy Allergan. It tells you all you need to know about the judgement being exercised when people like this are the chosen few.

Now how would a seasoned drug developer like Neil fit in here with these clowns as his peers?
Click to expand...

You suppose these executives have to sign the same non-compete as everyone else? I walked away from a good offer from Abbvie because of the non-compete, and because you could see the chaos clouds on the horizon from the Allergan merger.
 




anonymous said:
You suppose these executives have to sign the same non-compete as everyone else? I walked away from a good offer from Abbvie because of the non-compete, and because you could see the chaos clouds on the horizon from the Allergan merger.
Click to expand...
You would think so but so may of the leaders ended up at companies in the same therapeutic space so who knows.
 












For a brief time, Abbvie tried to be a true R&D company. That’s why they brought in basically everyone from Amgen, including Severino and Rob Scott.

But then they decided “F it, let’s just do what we always do. Buy stuff and make a patent thicket.”

So the people interested in inventing new drugs all left.
 




anonymous said:
For a brief time, Abbvie tried to be a true R&D company. That’s why they brought in basically everyone from Amgen, including Severino and Rob Scott.

But then they decided “F it, let’s just do what we always do. Buy stuff and make a patent thicket.”

So the people interested in inventing new drugs all left.
Click to expand...
So this is very accurate and in line with the Allergan Aesthetics acquisition. Anyone who has spent time with the ‘scientists’ realize they are more marketers than anything else.
 








anonymous said:
who downgraded? I suspect they all have more decision making rights and influence and probably more money. If you mean going to a smaller company, then true but maybe they actively wanted to seek that out after their experience at AbbVie.
Click to expand...
Nobody downgraded that’s what long timers think because they know nothing else.

The reality is a wonderful company for a chosen few everybody else is a mushroom.
 




anonymous said:
Nobody downgraded that’s what long timers think because they know nothing else.

The reality is a wonderful company for a chosen few everybody else is a mushroom.
Click to expand...
Exactly. Either they know nothing else, or are so addicted to their lifestyle that they could never imagine making a career decision based on something other than money.
 




Top Bottom
Back
Quote